Abstract
Pax5 is a transcription factor that is critical in the bone marrow for differentiation and proliferation of B cells until the plasma cell stage. In Pax5−/− mice, B-cell development stalls at the pro-B-cell stage. Messenger RNA profiles of alternatively spliced isoforms of Pax5 in bone marrow frequently differ between multiple myeloma (MM) patients and healthy donors. We sought to determine if Pax5 mRNA profiles also differed in blood and unexpectedly detected the presence of a previously unreported exon that alters the amino acid code for the transactivating domain of Pax5 in CD138− B cells. This unique exon escapes detection by conventional analyses of RT-PCR products and may serve as a prototype for other exons, in other genes, that escape RT-PCR detection. Eight percent of tested human subjects were heterozygous for an allele with a nonsynonymous nucleotide substitution in the new exon, and one MM patient was homozygotic for this base difference. Subsequent analysis of plasma and B-cell populations from bone marrow revealed a markedly reduced mRNA expression of the new isoform in cells from MM patients when compared to cells from normal subjects.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990) Basic local alignment search tool. J Mol Biol 215: 403–410
Barberis A, Widenhorn K, Vitelli L, Busslinger M (1990) A novel B-cell lineage-specific transcription factor present at early but not late stages of differentiation. Genes Dev 4: 849–859
Bedford MT, Sarbassova D, Xu J, Leder P, Yaffe MB (2000) A novel pro-Arg motif recognized by WW domains. J Biol Chem 14: 10359–10369
Borson NB, Lacy MQ, Wettstein PJ (2002) Altered mRNA expression of Pax5 and Blimp-1 B cells in multiple myeloma. Blood 100: 4629–4639
Chalepakis G, Jones FS, Edelman GM, Gruss P (1994) Pax-3 Contains domains for transcription activation and transcription inhibition. Proc Natl Acad Sci U S A 91: 12745–12749
Drewinko B, Mars W, Minowada J, Burk K, Trujillo J (1984) ARH-77, an established human IgG-producing myeloma cell line. Cancer 54: 1883–1892
Falquet L, Pagni M, Bucher P, Hulo N, Sigrist CJ, et al. (2002) The PROSITE database, its status in 2002. Nucleic Acids Res 30: 235–238
Hagman J, Wheat W, Fitzsimmons D, Hodsdon W, Negri J,et al. (2000) Pax-5/BSAP: regulator of specific gene expression and differentiation in B lymphocytes. Curr Top Microbiol Immuno. 245: 169–194
Hamada T, Yonetani N, Ueda C, Maesake Y, Akasaka H, et al. (1998) Expression of the PAX5/BSAP transcription factor in haematological tumour cells and further molecular characterization of the t(9:14)(p13;q32) translocation in B-cell non-Hodgkin’s lymphoma. Br J Haematol 102: 691–700
Jelinek DF, Ahmann GJ, Greipp PR, Jalal SM, Westendorf JJ, et al. (1993) Coexistence of aneuploid sub-clones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications. Cancer Res 53: 5320–5327
Kozmik A, Sure U, Ruedi D, Busslinger M (1995) Deregulated expression of PAX5 in medulloblastoma. Proc Natl Acad Sci U S A 92: 5709–5713
Lechner MS, Dressler GR (1996) Mapping of Pax-2 transcription activation domains. J Biol Chem 271: 21088–21093
Lewin B (1990) Mechanisms of RNA splicing. In Genes(Cambridge: Oxford University Press), IV, pp 596–597
Lin P, Mahdavy M, Zhan F, Zhang H, Katz RL, et al. (2004) Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray. odern Pathol 17: 1217–1222
Matsuoka Y, Moore GE, Yagi Y, Pressman D (1967) Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma. Proc Soc Exp Biol Med 125: 1246–1250
Rahman M, Hirabayashi Y, Ishii T, Kodera T, Watanabe M, et al. (2001) A repressor element in the 5′-untranslated region of human Pax5 exon 1A. Gene 263: 59–66
Robichaud G, Nardini M, Laflamme M, Cuperlovic-Culf M, Ouellette R (2004) Human Pax-5 C-terminal isoforms possess distinct transactivation properties and are differentially modulated in normal and malignant B cells. J Biol Chem 279: 49956–49963
Strehl S, Konig M, Dworzak MN, Kalwak K, Haas OA (2003) Pax5/ETV6 fusion defines cytogenetic entity dic(9;12)p13;p13. Leukemia 17: 1121–1123
Stuart ET, Kioussi C, Aguzzi A, Gruss P (1995) PAX5 expression correlates with increasing malignancy in human astrocytomas. Clin Cancer Res 1: 207–214
Westendorf JJ, Ahmann GJ, Greipp PR, Witzig TE, Kyle RA, et al. (1996) Establishment and characterization of three myeloma cell lines that demonstsrate variable cytokine responses and abilities to produce autocrine interleukin-6. Leukemia 10: 866–876
Zwollo P, Arrieta H, Ede K, Molinder K, Desiderio S, et al. (1997) The Pax-5 gene is alternatively spliced during B-cell development. J Biol Chem 272: 10160–10168
Acknowledgments
This work was supported in part by the grants Mayo-1: B-Cell (Mayo Clinic, Rochester, MN) and No. 2A2887 from the International Myeloma Foundation. The authors thank Diane F. Jelinek (Mayo Clinic, Rochester, MN) and Lei Peng (Johns Hopkins, Baltimore, MD) for the contribution of cell lines.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Borson, N.D., Lacy, M.Q. & Wettstein, P.J. Expression of mRNA for a newly identified Pax5 exon is reduced in multiple myeloma. Mamm Genome 17, 248–256 (2006). https://doi.org/10.1007/s00335-004-2433-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00335-004-2433-x